ArticleEJNMMI research2026
Early prognostic stratification of follicular lymphoma through ¹⁸F-FDG PET/CT tumor metabolic parameters and clinical characteristics.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFollicular lymphoma (FL), as the most common indolent lymphoma, exhibits reduced survival rates in patients with early progression compared to those without early progression. We aimed to develop a scoring system integrating baseline
resultsAmong 123 patients with FL, 33 (26.8%) experienced disease progression within 24 months of follow-up. Among clinical indicators, Lactate dehydrogenase (LDH) [OR: 3.267 (1.055, 10.117), P = 0.040] was an independent risk factor for POD24. Based on the receiver operating characteristic (ROC) curve, the optimal cutoff values for Total lesion glycolysis (TLG), total metabolic tumor volume (TMTV), maximum distance of spread (Dmax), and voxel-based maximum interlesion distance (DmaxVox) in POD24 patients were 628.59 g, 94.08 cm³, 37.22 cm, and 77.92 cm, respectively. Additionally, TLG > 628.59 g [OR: 5.1430 (1.9360, 13.6580), P = 0.001], TMTV > 94.08 cm³ [OR: 11.8530 (2.6730, 52.5640), P = 0.001], Dmax > 37.22 cm [OR: 3.0000 (1.1880, 8.6878), P = 0.028], and DmaxVox > 77.92 cm [OR: 8.0620 (2.2830, 28.4720), P = 0.001] were all risk factors for POD24 patients. The correlation heatmap revealed significant positive correlations between TLG and TMTV (r = 0.95) and between Dmax and DmaxVox (r = 0.99). Patients were stratified into three risk groups based on clinical LDH and imaging parameters TMTV and DmaxVox, with POD24 incidence rates of 5.7%, 26.1%, and 57.1%, respectively (P < 0.001). The constructed integrated model demonstrated the highest predictive performance for POD24 (AUC = 0.759). Decision curve analysis (DCA) and calibration curves confirmed the model's robust predictive capability.
conclusionsTMTV and DmaxVox on baseline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.